Cellectricon signs collaboration agreement with AstraZeneca
Advertisement
Cellectricon announced a collaboration with AstraZeneca, under which the companies will study the possibility of developing a new cell-based microfluidic screening platform. The collaboration aims to advance the performance of cell-based ion channel assays in screening applications.
"We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for drug discovery", says Dr. Mattias Karlsson, VP Research & Development at Cellectricon. "The fantastic market acceptance of Dynaflow, our first generation of microfluidic-based tools supports the unique possibilities the micro-scale format offers such as superior performance characteristics and robustness."